St. Jude Medical Trifecta aortic valve: Results from a prospective regional multicentre registry

Giovanni Mariscalco, Silvia Mariani, Samuele Bichi, Andrea Biondi, Andrea Blasio, Paolo Borsani, Fabrizio Corti, Benedetta De Chiara, Riccardo Gherli, Cristian Leva, Claudio Francesco Russo, Giordano Tasca, Paolo Vanelli, Ottavio Alfieri, Carlo Antona, Germano Di Credico, Giampiero Esposito, Amando Gamba, Luigi Martinelli, Lorenzo MenicantiGiovanni Paolini, Cesare Beghi

Research output: Contribution to journalArticle

Abstract

Background: The Trifecta aortic bioprosthesis (St. Jude Medical, Inc., St. Paul, MN, USA) is a stented pericardial heart valve with excellent preliminary results. Aim of the study was to evaluate its early clinical and hemodynamic performances in a multicenter regional registry. Methods: Between January 2011 and June 2012, 178 consecutive patients undergoing aortic valve replacement with the Trifecta bioprosthesis were prospectively enrolled at 9 Italian centers. Clinical and echocardiographic data were collectedat discharge, 6-months and at 1-year postoperatively. Results: The average age was 75.4 ± 7.7years,and 95 (53%) were men. Indication for valve replacement included stenosis in 123 patients (69%), mixed lesions in 25 (14%), and regurgitation in 30 (17%). Ninety-three (52%) patients were in NYHA functional class III/ IV. Hospital mortality accounted for 5 (2.8%) patients. No valve-related perioperative complications were encountered. Median follow-up was 20.5months (range: 1-34). Early (≤6months) complications included one thromboembolic event, one major bleeding, and 3 endocarditis (2 explants). Two late (>6months) thromboembolic events and two endocarditis (1 explant) were registered. No valve thrombosis or structural deterioration were observed after discharge. At 30-months, freedom from all-cause mortality was 87%, freedom from valve-related mortality 99.4%, freedom from endocarditis 97.5%, and freedom from valve explants 98%. At 1-year, mean gradients ranged from 8 to 16mmHg, and effective orifice area indexes from 1.0 to 1.2cm2/m2 for valve sizes from 19 to27 mm, respectively. No patients had severe prosthesis-patient mismatch. Conclusions: Trifecta bioprosthesis provided favourable clinical and hemodynamic results over time.

Original languageEnglish
Article number169
JournalJournal of Cardiothoracic Surgery
Volume10
Issue number1
DOIs
Publication statusPublished - Nov 20 2015

Fingerprint

Aortic Valve
Registries
Bioprosthesis
Endocarditis
Hemodynamics
Mortality
Heart Valves
Hospital Mortality
Prostheses and Implants
Pathologic Constriction
Thrombosis
Hemorrhage

Keywords

  • Aortic valve replacement
  • Biomaterials
  • Heart valve bioprosthesis
  • Heart valve replacement

ASJC Scopus subject areas

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Mariscalco, G., Mariani, S., Bichi, S., Biondi, A., Blasio, A., Borsani, P., ... Beghi, C. (2015). St. Jude Medical Trifecta aortic valve: Results from a prospective regional multicentre registry. Journal of Cardiothoracic Surgery, 10(1), [169]. https://doi.org/10.1186/s13019-015-0379-6

St. Jude Medical Trifecta aortic valve : Results from a prospective regional multicentre registry. / Mariscalco, Giovanni; Mariani, Silvia; Bichi, Samuele; Biondi, Andrea; Blasio, Andrea; Borsani, Paolo; Corti, Fabrizio; De Chiara, Benedetta; Gherli, Riccardo; Leva, Cristian; Russo, Claudio Francesco; Tasca, Giordano; Vanelli, Paolo; Alfieri, Ottavio; Antona, Carlo; Di Credico, Germano; Esposito, Giampiero; Gamba, Amando; Martinelli, Luigi; Menicanti, Lorenzo; Paolini, Giovanni; Beghi, Cesare.

In: Journal of Cardiothoracic Surgery, Vol. 10, No. 1, 169, 20.11.2015.

Research output: Contribution to journalArticle

Mariscalco, G, Mariani, S, Bichi, S, Biondi, A, Blasio, A, Borsani, P, Corti, F, De Chiara, B, Gherli, R, Leva, C, Russo, CF, Tasca, G, Vanelli, P, Alfieri, O, Antona, C, Di Credico, G, Esposito, G, Gamba, A, Martinelli, L, Menicanti, L, Paolini, G & Beghi, C 2015, 'St. Jude Medical Trifecta aortic valve: Results from a prospective regional multicentre registry', Journal of Cardiothoracic Surgery, vol. 10, no. 1, 169. https://doi.org/10.1186/s13019-015-0379-6
Mariscalco, Giovanni ; Mariani, Silvia ; Bichi, Samuele ; Biondi, Andrea ; Blasio, Andrea ; Borsani, Paolo ; Corti, Fabrizio ; De Chiara, Benedetta ; Gherli, Riccardo ; Leva, Cristian ; Russo, Claudio Francesco ; Tasca, Giordano ; Vanelli, Paolo ; Alfieri, Ottavio ; Antona, Carlo ; Di Credico, Germano ; Esposito, Giampiero ; Gamba, Amando ; Martinelli, Luigi ; Menicanti, Lorenzo ; Paolini, Giovanni ; Beghi, Cesare. / St. Jude Medical Trifecta aortic valve : Results from a prospective regional multicentre registry. In: Journal of Cardiothoracic Surgery. 2015 ; Vol. 10, No. 1.
@article{28a6a494bc1e4b7cb279c248b1d0494c,
title = "St. Jude Medical Trifecta aortic valve: Results from a prospective regional multicentre registry",
abstract = "Background: The Trifecta aortic bioprosthesis (St. Jude Medical, Inc., St. Paul, MN, USA) is a stented pericardial heart valve with excellent preliminary results. Aim of the study was to evaluate its early clinical and hemodynamic performances in a multicenter regional registry. Methods: Between January 2011 and June 2012, 178 consecutive patients undergoing aortic valve replacement with the Trifecta bioprosthesis were prospectively enrolled at 9 Italian centers. Clinical and echocardiographic data were collectedat discharge, 6-months and at 1-year postoperatively. Results: The average age was 75.4 ± 7.7years,and 95 (53{\%}) were men. Indication for valve replacement included stenosis in 123 patients (69{\%}), mixed lesions in 25 (14{\%}), and regurgitation in 30 (17{\%}). Ninety-three (52{\%}) patients were in NYHA functional class III/ IV. Hospital mortality accounted for 5 (2.8{\%}) patients. No valve-related perioperative complications were encountered. Median follow-up was 20.5months (range: 1-34). Early (≤6months) complications included one thromboembolic event, one major bleeding, and 3 endocarditis (2 explants). Two late (>6months) thromboembolic events and two endocarditis (1 explant) were registered. No valve thrombosis or structural deterioration were observed after discharge. At 30-months, freedom from all-cause mortality was 87{\%}, freedom from valve-related mortality 99.4{\%}, freedom from endocarditis 97.5{\%}, and freedom from valve explants 98{\%}. At 1-year, mean gradients ranged from 8 to 16mmHg, and effective orifice area indexes from 1.0 to 1.2cm2/m2 for valve sizes from 19 to27 mm, respectively. No patients had severe prosthesis-patient mismatch. Conclusions: Trifecta bioprosthesis provided favourable clinical and hemodynamic results over time.",
keywords = "Aortic valve replacement, Biomaterials, Heart valve bioprosthesis, Heart valve replacement",
author = "Giovanni Mariscalco and Silvia Mariani and Samuele Bichi and Andrea Biondi and Andrea Blasio and Paolo Borsani and Fabrizio Corti and {De Chiara}, Benedetta and Riccardo Gherli and Cristian Leva and Russo, {Claudio Francesco} and Giordano Tasca and Paolo Vanelli and Ottavio Alfieri and Carlo Antona and {Di Credico}, Germano and Giampiero Esposito and Amando Gamba and Luigi Martinelli and Lorenzo Menicanti and Giovanni Paolini and Cesare Beghi",
year = "2015",
month = "11",
day = "20",
doi = "10.1186/s13019-015-0379-6",
language = "English",
volume = "10",
journal = "Journal of Cardiothoracic Surgery",
issn = "1749-8090",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - St. Jude Medical Trifecta aortic valve

T2 - Results from a prospective regional multicentre registry

AU - Mariscalco, Giovanni

AU - Mariani, Silvia

AU - Bichi, Samuele

AU - Biondi, Andrea

AU - Blasio, Andrea

AU - Borsani, Paolo

AU - Corti, Fabrizio

AU - De Chiara, Benedetta

AU - Gherli, Riccardo

AU - Leva, Cristian

AU - Russo, Claudio Francesco

AU - Tasca, Giordano

AU - Vanelli, Paolo

AU - Alfieri, Ottavio

AU - Antona, Carlo

AU - Di Credico, Germano

AU - Esposito, Giampiero

AU - Gamba, Amando

AU - Martinelli, Luigi

AU - Menicanti, Lorenzo

AU - Paolini, Giovanni

AU - Beghi, Cesare

PY - 2015/11/20

Y1 - 2015/11/20

N2 - Background: The Trifecta aortic bioprosthesis (St. Jude Medical, Inc., St. Paul, MN, USA) is a stented pericardial heart valve with excellent preliminary results. Aim of the study was to evaluate its early clinical and hemodynamic performances in a multicenter regional registry. Methods: Between January 2011 and June 2012, 178 consecutive patients undergoing aortic valve replacement with the Trifecta bioprosthesis were prospectively enrolled at 9 Italian centers. Clinical and echocardiographic data were collectedat discharge, 6-months and at 1-year postoperatively. Results: The average age was 75.4 ± 7.7years,and 95 (53%) were men. Indication for valve replacement included stenosis in 123 patients (69%), mixed lesions in 25 (14%), and regurgitation in 30 (17%). Ninety-three (52%) patients were in NYHA functional class III/ IV. Hospital mortality accounted for 5 (2.8%) patients. No valve-related perioperative complications were encountered. Median follow-up was 20.5months (range: 1-34). Early (≤6months) complications included one thromboembolic event, one major bleeding, and 3 endocarditis (2 explants). Two late (>6months) thromboembolic events and two endocarditis (1 explant) were registered. No valve thrombosis or structural deterioration were observed after discharge. At 30-months, freedom from all-cause mortality was 87%, freedom from valve-related mortality 99.4%, freedom from endocarditis 97.5%, and freedom from valve explants 98%. At 1-year, mean gradients ranged from 8 to 16mmHg, and effective orifice area indexes from 1.0 to 1.2cm2/m2 for valve sizes from 19 to27 mm, respectively. No patients had severe prosthesis-patient mismatch. Conclusions: Trifecta bioprosthesis provided favourable clinical and hemodynamic results over time.

AB - Background: The Trifecta aortic bioprosthesis (St. Jude Medical, Inc., St. Paul, MN, USA) is a stented pericardial heart valve with excellent preliminary results. Aim of the study was to evaluate its early clinical and hemodynamic performances in a multicenter regional registry. Methods: Between January 2011 and June 2012, 178 consecutive patients undergoing aortic valve replacement with the Trifecta bioprosthesis were prospectively enrolled at 9 Italian centers. Clinical and echocardiographic data were collectedat discharge, 6-months and at 1-year postoperatively. Results: The average age was 75.4 ± 7.7years,and 95 (53%) were men. Indication for valve replacement included stenosis in 123 patients (69%), mixed lesions in 25 (14%), and regurgitation in 30 (17%). Ninety-three (52%) patients were in NYHA functional class III/ IV. Hospital mortality accounted for 5 (2.8%) patients. No valve-related perioperative complications were encountered. Median follow-up was 20.5months (range: 1-34). Early (≤6months) complications included one thromboembolic event, one major bleeding, and 3 endocarditis (2 explants). Two late (>6months) thromboembolic events and two endocarditis (1 explant) were registered. No valve thrombosis or structural deterioration were observed after discharge. At 30-months, freedom from all-cause mortality was 87%, freedom from valve-related mortality 99.4%, freedom from endocarditis 97.5%, and freedom from valve explants 98%. At 1-year, mean gradients ranged from 8 to 16mmHg, and effective orifice area indexes from 1.0 to 1.2cm2/m2 for valve sizes from 19 to27 mm, respectively. No patients had severe prosthesis-patient mismatch. Conclusions: Trifecta bioprosthesis provided favourable clinical and hemodynamic results over time.

KW - Aortic valve replacement

KW - Biomaterials

KW - Heart valve bioprosthesis

KW - Heart valve replacement

UR - http://www.scopus.com/inward/record.url?scp=84947546527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947546527&partnerID=8YFLogxK

U2 - 10.1186/s13019-015-0379-6

DO - 10.1186/s13019-015-0379-6

M3 - Article

AN - SCOPUS:84947546527

VL - 10

JO - Journal of Cardiothoracic Surgery

JF - Journal of Cardiothoracic Surgery

SN - 1749-8090

IS - 1

M1 - 169

ER -